Clinical Trial Update: A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intravenous or subcutaneous methoxy polyethylene glycol-epoetin beta (Mircera) in chronic kidney disease patients with renal anemia has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• MIRCERA (METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Anemia | Phase 3 | Status: COMPLETED | Results posted: 2012-01-05